Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Outlook Therapeutics, Inc. (41ON.SG)

Compare

6.24

0.00

(0.00%)

At close: March 12 at 8:55:34 PM GMT+1

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, an investigat

GlobeNewswire 6 days ago

OTLK
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference. As part of th

GlobeNewswire 15 days ago

OTLK
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an op

GlobeNewswire 20 days ago

OTLK
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial Watch the “What This Means” segment here ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular dege

GlobeNewswire 30 days ago

OTLK
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role

GlobeNewswire last month

OTLK
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safetyONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeksCompany on track for anticipated BLA resubmission in calendar Q1 2025 ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval

GlobeNewswire last month

OTLK
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:00 PM ETISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Lawrence A. Kenyon, Executive Vice President, CFO and Inte

GlobeNewswire last month

OTLK
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in gross proceeds ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an

GlobeNewswire last month

OTLK
Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics ( (OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its investors. Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for retinal diseases, particularly wet age-related macular degeneration (AMD), with its product LYTENA V A™ being the first approved ophthalmic formulation of bevacizumab in the EU and UK. The company recently announced its financial results for

TipRanks 2 months ago

OTLK
Outlook Therapeutics provides ONS-5010/LYTENAVA update

In May 2024, the European Commission granted Marketing Authorization for LYTENAVA for the treatment of wet AMD in the EU. Additionally, in July 2024, the UK Medicines and Healthcare products Regulatory Agency granted Marketing Authorization for LYTENAVA for the same indication in the UK. In December 2024, the National Institute for Health and Care Excellence recommended LYTENAVA as an option for the treatment of wet AMD. Plans for a potential 2025 launch in the UK and Germany are ongoing. Outloo

TipRanks 2 months ago

OTLK
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli

GlobeNewswire 2 months ago

OTLK
Outlook Therapeutics® Streamlines Operations

Full NORSE EIGHT Data Readout Expected January 2025ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board

GlobeNewswire 2 months ago

OTLK
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 new wet AMD patients each year in the UK who could benefit from treatment1 ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the

GlobeNewswire 2 months ago

OTLK
Outlook Therapeutics® Announces Executive Leadership Transition

ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company’s President and Chief Executive Officer (C

GlobeNewswire 3 months ago

OTLK
Outlook Therapeutics price target lowered to $9 from $50 at BTIG

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary endpoint in NORSE EIGHT despite the difference between ONS-5010 and ranibizumab falling within the pre-specified noninferiority margin at eight weeks. Despite NORSE EIGHT technically not meeting its primary endpoint, BTIG remains Buy rated. Outlook is now trading at a zero enterprise value, there is still

TipRanks 3 months ago

OTLK
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced preliminary topline results of

GlobeNewswire 3 months ago

OTLK
Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Key Insights Given the large stake in the stock by institutions, Outlook Therapeutics' stock price might be vulnerable...

Simply Wall St. 3 months ago

OTLK
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ETISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Th

GlobeNewswire 3 months ago

OTLK
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics participated in a Virtual

GlobeNewswire 4 months ago

OTLK
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ETISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced t

GlobeNewswire 5 months ago

OTLK

Performance Overview

Return	41ON.SG	S&P 500
YTD	+230.16%	-2.43%
1-Year	-14.29%	+12.42%
3-Year	-79.82%	+32.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Outlook Therapeutics, Inc. (41ON.SG)

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Outlook Therapeutics Reports 2024 Financial Results

Outlook Therapeutics provides ONS-5010/LYTENAVA update

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Streamlines Operations

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Outlook Therapeutics® Announces Executive Leadership Transition

Outlook Therapeutics price target lowered to $9 from $50 at BTIG

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Owning 30% shares,institutional owners seem interested in Outlook Therapeutics, Inc. (NASDAQ:OTLK),

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Performance Overview